



(51) International Patent Classification:

C07K 14/65 (2006.01) A61K 48/00 (2006.01)
C12N 15/85 (2006.01) A61P 25/02 (2006.01)
A61K 38/30 (2006.01)

(21) International Application Number:

PCT/IB2019/000843

(22) International Filing Date:

16 July 2019 (16.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/699,662 17 July 2018 (17.07.2018) US

(71) Applicant: **HELIXMITH CO., LTD.** [KR/KR]; Building 203, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826 (KR).

(72) Inventors: **LEE, Junghun**; Helixmith Co., Ltd., Building 203, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826 (KR). **LEE, Nayeon**; Helixmith Co., Ltd., Building 203, Seoul National University, 1 Gwanak-ro,

Gwanak-gu, Seoul 08826 (KR). **KO, Kyeong Ryang**; Helixmith Co., Ltd., Building 203, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTS EXPRESSING IGF-1 ISOFORMS




FIG 5B

(57) Abstract: The present invention relates to a DNA construct encoding one or more human IGF-1 isoforms that can be used for treatment of neuropathy. Further provided herein are a pharmaceutical composition including the DNA construct as an active ingredient and a method of administering the DNA construct for treatment of neuropathy. The present invention provides a safe and effective way of treating neuropathic patients.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

12 March 2020 (12.03.2020)